Programa de Pós-Graduação em Genética e Biologia Molecular, Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre, Brazil.
Laboratório de Medicina Genômica, Centro de Pesquisa Experimental do Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil.
PLoS One. 2018 Dec 31;13(12):e0209934. doi: 10.1371/journal.pone.0209934. eCollection 2018.
Premenopausal breast cancer (BC) is a core tumor of Li-Fraumeni (LFS) and Li-Fraumeni-like (LFL) Syndromes, predisposition disorders caused by germline mutations in TP53 gene. In the Southern and Southeastern regions of Brazil, a specific TP53 germline mutation, c.1010G>A (p.Arg337His), was identified at a population frequency of 0.3%, the highest value ever described for a TP53 germline variation. In Brazilian BC patients, carrier frequency can vary from 0.5% to 8.7%. The current study assessed carrier frequency by genotyping TP53 c.1010G>A in 2 BC groups: 1) 315 patients unselected for age of diagnosis and family history (FH) and 2) 239 patients diagnosed before 46 years and without Chompret criteria for LFS or LFL. One carrier was identified in group 1 (0.3%; CI 95% 0.1-1.76%) and six carriers in group 2 (2.5%; CI 95% 0.93-5.39%). The frequencies differed significantly between groups (p = 0.04). The mutation carrier frequency observed in group 2 could justify mutation testing in BC patients diagnosed before 46 years and without Chompret criteria for LFS or LFL. Further studies in larger samples of BC patients of different ages and regions of the country are necessary to provide more definitive TP53 p.Arg337His carrier frequencies in different scenarios.
绝经前乳腺癌(BC)是 Li-Fraumeni(LFS)和 Li-Fraumeni 样(LFL)综合征的核心肿瘤,是由 TP53 基因突变引起的种系易感性疾病。在巴西南部和东南部地区,发现了一种特定的 TP53 种系突变 c.1010G>A(p.Arg337His),其人群频率为 0.3%,这是有史以来描述的 TP53 种系变异的最高值。在巴西 BC 患者中,携带者频率可从 0.5%到 8.7%不等。本研究通过基因分型 TP53 c.1010G>A 评估了 2 个 BC 组的携带者频率:1)315 名未选择诊断年龄和家族史(FH)的患者;2)239 名诊断年龄在 46 岁之前且不符合 LFS 或 LFL 的 Chompret 标准的患者。在第 1 组中发现了 1 名携带者(0.3%;95%CI 0.1-1.76%),在第 2 组中发现了 6 名携带者(2.5%;95%CI 0.93-5.39%)。两组之间的频率差异具有统计学意义(p = 0.04)。在第 2 组中观察到的突变携带者频率可能证明对诊断年龄在 46 岁之前且不符合 LFS 或 LFL 的 Chompret 标准的 BC 患者进行突变检测是合理的。在不同年龄段和不同地区的更大样本的 BC 患者中进行进一步的研究,对于在不同情况下提供更明确的 TP53 p.Arg337His 携带者频率是必要的。